# Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery

> **NCT02500797** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 164 (actual)

## Conditions studied

- Locally Advanced Bone Sarcoma
- Locally Advanced Dedifferentiated Liposarcoma
- Locally Advanced Gastrointestinal Stromal Tumor
- Locally Advanced Soft Tissue Sarcoma
- Metastatic Bone Sarcoma
- Metastatic Liposarcoma
- Metastatic Soft Tissue Sarcoma
- Metastatic Undifferentiated Pleomorphic Sarcoma
- Metastatic Unresectable Sarcoma
- Pleomorphic Liposarcoma
- Stage III Bone Sarcoma AJCC v7
- Stage III Soft Tissue Sarcoma AJCC v7
- Stage IV Bone Sarcoma AJCC v7
- Stage IV Soft Tissue Sarcoma AJCC v7
- Stage IVA Bone Sarcoma AJCC v7
- Stage IVB Bone Sarcoma AJCC v7
- Unresectable Bone Sarcoma
- Unresectable Dedifferentiated Liposarcoma
- Unresectable Liposarcoma
- Unresectable Malignant Gastrointestinal Stromal Tumor
- Unresectable Soft Tissue Sarcoma

## Interventions

- **BIOLOGICAL:** Ipilimumab
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Nivolumab
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT02500797
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-13
- **Primary completion:** 2019-04-01
- **Final completion:** 2023-04-01
- **Target enrollment:** 164 (ACTUAL)
- **Last updated:** 2023-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02500797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02500797, "Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02500797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*